Cancer Cell Signaling Prgm

癌细胞信号转导方案

• 批准号: 9365066
• 负责人: GORDON D GINDER
• 金额: $ 7.69万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9365066
• 关键词: Affect; Bioenergetics; Cancer Center; Cancer Center Support Grant; Cell Survival; Cellular biology; Clinical; Collaborations; Development; Direct Costs; Environment; Event; Fostering; Funding; Funding Agency; Genes; Genetic Programming; Goals; Grant; Humanities; Inflammation; Instruction; Laboratory Study; Lipids; Malignant Neoplasms; Molecular; Molecular Genetics; Peer Review; Phase I/II Trial; Publications; Research; Research Personnel; Role; Science; Signal Pathway; Signal Transduction; Transgenic Model; United States National Institutes of Health; Universities; Virginia; Xenograft Model; anticancer research; base; cancer cell; cell behavior; college; inhibitor/antagonist; interdisciplinary approach; interest; medical schools; meetings; multidisciplinary; neoplastic cell; pre-clinical; programs; success; therapeutic target; tumor; tumorigenesis

The Cancer Cell Signaling (CCS) program is a newly formed program resulting from the restructuring of the former Cancer Cell Biology program into two more cohesive programs [the other being the Cancer Molecular Genetics program (CMG)]. The CCS program consists of a multidisciplinary group of 18 investigators from 6 academic departments from the School of Medicine and the College of Humanities and Sciences, who share a common interest in elucidation of cellular and molecular signaling events governing neoplastic cell behavior and survival. They also share the overarching scientific goals of: 1) examining the role of bioactive lipids in tumor formation; 2) identifying key signaling pathways that are perturbed in cancer cells; 3) understanding the interactions among metabolites, inflammation, bioenergetics, genes, and the environment that affect tumorigenesis; and 4) identifying potential therapeutic targets and strategies based upon an understanding of cancer cell signaling and to develop a rational basis for combining inhibitors of these. The CCS program also has a strong pre-clinical thrust with investigators utilizing xenograft and transgenic models seeking to develop treatments involving agents that act by modulating various signal transduction networks. The CCS program has a funding base of roughly $6.8 million dollars in annual direct support, of which $6.25 is from NIH and other peer-reviewed funding sources. The funding base includes 9 funded projects from NCI with a total of $1.4 million in annual direct costs. CCS fosters the development of intra and inter-programmatic interactions by organizing seminars and regular meetings among the entire program membership, as well as focused discussion groups with overlapping research interests that have led to numerous co-publications and new collaborative grants. The success of this broad, interdisciplinary approach to cancer research is demonstrated by the track record of CCS program investigators with 260 publications since 2008 of which 15% represent intra-programmatic collaborations, 34% represent inter-programmatic collaborations, and 5% both intra and inter-programmatic collaborations, and in developing initiatives that have progressed from basic laboratory studies to 8 multi-institutional clinical Phase I/II trials with other Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) programs.

癌症细胞信号传导（CCS）计划是一个新成立的计划，由于重组， 前癌症细胞生物学计划分为两个更具凝聚力的计划[另一个是癌症分子 遗传学程序（CMG）]。CCS项目由来自6个国家的18名研究人员组成的多学科小组组成。 来自医学院和人文与科学学院的学术部门，他们分享 共同的兴趣是阐明控制肿瘤细胞的细胞和分子信号事件， 行为与生存他们还分享了总体科学目标：1）研究生物活性物质的作用， 脂质在肿瘤形成中的作用; 2）识别在癌细胞中受到干扰的关键信号通路; 3） 了解代谢物，炎症，生物能量学，基因和环境之间的相互作用 影响肿瘤发生;和4）基于肿瘤发生的可能性，鉴定潜在的治疗靶点和策略。 了解癌细胞信号传导，并为这些抑制剂的组合开发合理的基础。的 CCS项目也具有强大的临床前推力，研究人员利用异种移植和转基因技术 寻求开发涉及通过调节各种信号转导而起作用的药剂的治疗的模型 网络. CCS计划的资金基础约为每年680万美元的直接支持， 其中6.25美元来自NIH和其他同行评审的资金来源。资金来源包括9项资助 国家癌症研究所的项目每年直接费用共计140万美元。CCS促进内部和 通过组织研讨会和定期会议，在整个方案中进行方案间的互动 成员，以及重点讨论小组与重叠的研究兴趣，导致 许多共同出版物和新的合作赠款。这个广泛的跨学科的 CCS项目研究人员的跟踪记录证明了癌症研究的方法， 自2008年以来的出版物，其中15%为计划内合作，34%为计划间合作 合作，5%的内部和跨方案合作，并在开发 从基础实验室研究进展到8项多机构I/II期临床试验的举措 与其他弗吉尼亚联邦大学（VCU）梅西癌症中心（MCC）计划。